OncoMatch/Clinical Trials/NCT05848765
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Is NCT05848765 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for relapsed follicular lymphoma.
Treatment: Epcoritamab · Lenalidomide · Rituximab · Obinutuzumab · Bendamustine · Vincristine · Doxorubicin · Cyclophosphamide · Prednisone · Investigation agent 2 · Investigation agent 3 — The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunochemotherapy
Prior therapy with at least one line of immunochemotherapy
Cannot have received: allogenic stem cell transplantation
Prior allogenic stem cell transplantation (SCT) or solid organ transplant
Cannot have received: solid organ transplant
Prior allogenic stem cell transplantation (SCT) or solid organ transplant
Cannot have received: lenalidomide (lenalidomide)
Prior treatment with lenalidomide
Cannot have received: CAR-T cell therapy
Exception: within 100 days of starting trial treatment
Treatment with CAR-T therapy within 100 days of starting trial treatment
Cannot have received: immunochemotherapy with a platinum-containing regimen
Exception: planned
Immunochemotherapy with a platinum-containing regimen planned
Cannot have received: experimental therapy under investigation
Prior treatment with the experimental therapy under investigation
Lab requirements
Blood counts
ANC ≥ 1.0 x 10^9/L (growth factor use is permitted); Platelet count ≥ 75 x 10^9/L, or ≥ 50 x 10^9/L if bone marrow infiltration or splenomegaly
Kidney function
CrCl ≥ 50mL/min (by Cockcroft-Gault formula)
Liver function
ALT and AST level ≤3 x ULN; Direct bilirubin level ≤ 2 x ULN, unless due to Gilbert's syndrome
Cardiac function
LVEF within normal limits by MUGA or echocardiography
Adequate organ function defined as; i. ANC ≥ 1.0 x 10^9/L (growth factor use is permitted) ii. Platelet count ≥ 75 x 10^9/L, or ≥ 50 x 10^9/L if bone marrow infiltration or splenomegaly iii. ALT and AST level ≤3 x ULN iv. Direct bilirubin level ≤ 2 x ULN, unless due to Gilbert's syndrome v. CrCl ≥ 50mL/min (by Cockcroft-Gault formula) vi. PT, INR and aPTT ≤ 1.5 x ULN, unless receiving anticoagulation vii. LVEF within normal limits by MUGA or echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05848765 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogenic stem cell transplantation, solid organ transplant, lenalidomide disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages